Do analysts rate ABVC or VRCA?

Verrica Pharmaceuticals has a consensus price target of $12.67, suggesting a potential upside of 122.61%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts rate ABVC or ELOX?

Eloxx Pharmaceuticals has a consensus target price of $41.50, suggesting a potential upside of 175.38%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eloxx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is ABVC or ELOX more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Eloxx Pharmaceuticals N/A N/A N/A

Do analysts rate ABVC or MNOV?

MediciNova has a consensus price target of $8.33, suggesting a potential upside of 480.72%. Given MediciNova's stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Do analysts rate LONA or ABVC?

Athira Pharma currently has a consensus price target of $17.33, indicating a potential upside of 118.30%. Given Athira Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Athira Pharma is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, LONA or ABVC?

ABVC BioPharma is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$4.21 N/A ABVC BioPharma N/A N/A -$7.91M -$0.30 N/A

Is LONA or ABVC more profitable?

ABVC BioPharma's return on equity of -47.68% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% ABVC BioPharma N/A -47.68% -30.97%

Do analysts prefer ABVC or SPRO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

ABVC BioPharma (ABVC) Competitors

$0.83 +0.03 (+4.31%)

As of 08/28/2026 04:00 PM Eastern

Compare

ABVC vs. VRCA, ELOX, MNOV, LONA, and SPRO

Should you buy ABVC BioPharma stock or one of its competitors? ABVC BioPharma's main competitors and comparable companies include Verrica Pharmaceuticals (VRCA), Eloxx Pharmaceuticals (ELOX), MediciNova (MNOV), Athira Pharma (LONA), and Spero Therapeutics (SPRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ABVC BioPharma compare to Verrica Pharmaceuticals?

ABVC BioPharma (NASDAQ:ABVC) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ABVC BioPharma has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.30	N/A
Verrica Pharmaceuticals	$30.32M	3.22	-$17.89M	-$1.67	N/A

In the previous week, Verrica Pharmaceuticals had 6 more articles in the media than ABVC BioPharma. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.89 beat Verrica Pharmaceuticals' score of 0.41 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ABVC BioPharma	Very Positive
Verrica Pharmaceuticals	Neutral

ABVC BioPharma has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Verrica Pharmaceuticals has a consensus price target of $12.67, suggesting a potential upside of 122.61%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

ABVC BioPharma has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. ABVC BioPharma's return on equity of -47.68% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%

Summary

Verrica Pharmaceuticals beats ABVC BioPharma on 8 of the 15 factors compared between the two stocks.

How does ABVC BioPharma compare to Eloxx Pharmaceuticals?

ABVC BioPharma (NASDAQ:ABVC) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

ABVC BioPharma has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1864.08, suggesting that its stock price is 186,508% less volatile than the broader market.

Eloxx Pharmaceuticals' return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Eloxx Pharmaceuticals has a consensus target price of $41.50, suggesting a potential upside of 175.38%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Eloxx Pharmaceuticals has higher revenue and earnings than ABVC BioPharma. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.30	N/A
Eloxx Pharmaceuticals	$6.36M	9.57	-$5.99M	-$1.54	N/A

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.89 beat Eloxx Pharmaceuticals' score of 0.62 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ABVC BioPharma	Very Positive
Eloxx Pharmaceuticals	Positive

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Eloxx Pharmaceuticals beats ABVC BioPharma on 10 of the 15 factors compared between the two stocks.

How does ABVC BioPharma compare to MediciNova?

ABVC BioPharma (NASDAQ:ABVC) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

ABVC BioPharma has higher earnings, but lower revenue than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.30	N/A
MediciNova	$410K	172.27	-$12M	-$0.21	N/A

ABVC BioPharma has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

MediciNova has a consensus price target of $8.33, suggesting a potential upside of 480.72%. Given MediciNova's stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

ABVC BioPharma has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
MediciNova	-1,168.70%	-26.51%	-24.39%

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, MediciNova had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for MediciNova and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.89 beat MediciNova's score of 0.88 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ABVC BioPharma	Very Positive
MediciNova	Positive

Summary

MediciNova beats ABVC BioPharma on 10 of the 16 factors compared between the two stocks.

How does ABVC BioPharma compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

In the previous week, Athira Pharma and Athira Pharma both had 1 articles in the media. Athira Pharma's average media sentiment score of 1.89 equaled ABVC BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Athira Pharma	Very Positive
ABVC BioPharma	Very Positive

Athira Pharma currently has a consensus price target of $17.33, indicating a potential upside of 118.30%. Given Athira Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Athira Pharma is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma's return on equity of -47.68% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
ABVC BioPharma	N/A	-47.68%	-30.97%

Athira Pharma has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

ABVC BioPharma is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.30	N/A

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Athira Pharma beats ABVC BioPharma on 7 of the 11 factors compared between the two stocks.

How does ABVC BioPharma compare to Spero Therapeutics?

ABVC BioPharma (NASDAQ:ABVC) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

ABVC BioPharma has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.30	N/A
Spero Therapeutics	$42.96M	1.63	$8.57M	$0.11	10.91

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spero Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, ABVC BioPharma and ABVC BioPharma both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 1.89 beat Spero Therapeutics' score of 0.94 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ABVC BioPharma	Very Positive
Spero Therapeutics	Positive

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Spero Therapeutics has a net margin of 24.90% compared to ABVC BioPharma's net margin of 0.00%. Spero Therapeutics' return on equity of 16.17% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Spero Therapeutics	24.90%	16.17%	12.57%

Summary

Spero Therapeutics beats ABVC BioPharma on 10 of the 12 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVC vs. The Competition

Export

Metric	ABVC BioPharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.12M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-2.77	787.65	273.16	25.45
Price / Sales	N/A	793.10	604.48	76.58
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	1.80	11.97	12.98	6.14
Net Income	-$7.91M	$2.83B	$3.48B	$348.86M
7 Day Performance	-6.73%	0.39%	0.13%	-0.80%
1 Month Performance	-23.15%	5.34%	7.08%	4.13%
1 Year Performance	-70.67%	6.05%	24.67%	15.17%

ABVC BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVC ABVC BioPharma	0.8425 of 5 stars	$0.83 +4.3%	N/A	-70.7%	$22.12M	N/A	N/A	30	Positive News Gap Up
VRCA Verrica Pharmaceuticals	4.1864 of 5 stars	$4.91 -0.6%	$14.50 +195.3%	+1.8%	$84.86M	$35.58M	N/A	40	News Coverage Analyst Forecast
ELOX Eloxx Pharmaceuticals	3.0812 of 5 stars	$18.53 -3.9%	$41.50 +124.0%	N/A	$77.86M	$6.36M	N/A	N/A
MNOV MediciNova	2.0279 of 5 stars	$1.48 -5.7%	$8.33 +463.1%	+9.5%	$77.28M	$410K	N/A	10
LONA Athira Pharma	3.7884 of 5 stars	$7.81 -2.5%	$17.33 +121.9%	N/A	$75.24M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVC) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ABVC BioPharma (ABVC) Competitors

ABVC vs. VRCA, ELOX, MNOV, LONA, and SPRO

How does ABVC BioPharma compare to Verrica Pharmaceuticals?

Summary

How does ABVC BioPharma compare to Eloxx Pharmaceuticals?

Summary

How does ABVC BioPharma compare to MediciNova?

Summary

How does ABVC BioPharma compare to Athira Pharma?

Summary

How does ABVC BioPharma compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ABVC BioPharma (ABVC) Competitors

ABVC vs. VRCA, ELOX, MNOV, LONA, and SPRO

How does ABVC BioPharma compare to Verrica Pharmaceuticals?

Do institutionals & insiders have more ownership in ABVC or VRCA?

Which has better earnings and valuation, ABVC or VRCA?

Does the media favor ABVC or VRCA?

Which has more volatility & risk, ABVC or VRCA?

Do analysts rate ABVC or VRCA?

Is ABVC or VRCA more profitable?

Summary

How does ABVC BioPharma compare to Eloxx Pharmaceuticals?

Which has more risk and volatility, ABVC or ELOX?

Is ABVC or ELOX more profitable?

Do analysts rate ABVC or ELOX?

Which has higher valuation and earnings, ABVC or ELOX?

Does the media favor ABVC or ELOX?

Do insiders & institutionals have more ownership in ABVC or ELOX?

Summary

How does ABVC BioPharma compare to MediciNova?

Which has preferable valuation & earnings, ABVC or MNOV?

Which has more risk & volatility, ABVC or MNOV?

Do analysts rate ABVC or MNOV?

Is ABVC or MNOV more profitable?

Do insiders and institutionals have more ownership in ABVC or MNOV?

Does the media favor ABVC or MNOV?

Summary

How does ABVC BioPharma compare to Athira Pharma?

Does the media prefer LONA or ABVC?

Do analysts rate LONA or ABVC?

Is LONA or ABVC more profitable?

Which has more volatility & risk, LONA or ABVC?

Which has higher valuation & earnings, LONA or ABVC?

Do insiders & institutionals believe in LONA or ABVC?

Summary

How does ABVC BioPharma compare to Spero Therapeutics?

Which has more risk & volatility, ABVC or SPRO?

Which has higher earnings and valuation, ABVC or SPRO?

Do analysts prefer ABVC or SPRO?

Does the media favor ABVC or SPRO?

Do insiders & institutionals have more ownership in ABVC or SPRO?

Is ABVC or SPRO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools